uniQure Files the First Gene Therapy Application for Huntington's Disease

uniQure said on September 2, 2026 that it has submitted a biologics license application to the US Food and Drug Administration for AMT-130, its experimental gene therapy for Huntington's disease, and that it has separately applied for approval in the United Kingdom, marking the first regulatory filings for a gene therapy targeting the fatal neurodegenerative disorder. BioSpace reported on Sep 2 that the submissions come after months of regulatory maneuvering in which the FDA first raised doubts about whether the company's mid-stage data could support approval, then reversed course in June 2026 and reopened a path toward accelerated approval. The company said it is grateful to the FDA for its leadership in advancing regulatory science to meet the urgency of the disease, a statement that reflects how much the filing depended on a shift in the agency's position.

Huntington's disease is caused by a single mutation in the huntingtin gene, which makes it one of the most tractable targets for gene therapy: correct or silence the mutant gene and you address the root cause, not just the symptoms. The disease typically strikes in mid-adulthood and progressively destroys motor control, cognition and emotional stability, with no therapy currently available that slows its course. AMT-130 is designed to deliver a silencing mechanism directly to the brain through a one-time surgical procedure, and the Phase I/II data that uniQure has accumulated over several years represent the most advanced clinical evidence ever generated for a Huntington's gene therapy. The filing is the culmination of that effort, and it sets up a regulatory decision that could reshape the treatment landscape for a disease that has seen almost no therapeutic progress in decades.

Key Facts

BioSpace reported on Sep 2 that uniQure submitted a BLA to the FDA for AMT-130 and separately applied to the UK's Medicines and Healthcare products Regulatory Agency, or MHRA, for approval of the therapy. The company said in its Sep 2 announcement that AMT-130 holds Breakthrough Therapy, Regenerative Medicine Advanced Therapy, or RMAT, and Fast Track designations from the FDA, with the RMAT designation described as the first granted for Huntington's disease. allsci.com reported on Sep 2 that uniQure intends to present four-year data from its ongoing Phase I/II studies before the end of the third quarter of 2026, which would give regulators the longest follow-up yet on patients treated with the therapy.

The regulatory path was anything but smooth. In early 2026, the FDA told uniQure that data from the Phase I/II study, which compared treated patients against an external natural-history control group, were not sufficient to support a marketing application, and the agency demanded a prospective, randomized, double-blind, sham-surgery-controlled Phase III trial, according to Fierce Biotech's coverage of the setback. Then, in a June 17, 2026 meeting, the FDA reversed course and confirmed that three-year data from the study could support an accelerated approval filing, a decision that Fierce Biotech and Global Genes both described as a significant shift in the agency's approach to advanced genetic medicines. That reversal set up the Sep 2 filing.

The science behind AMT-130 is a one-time intervention. The therapy uses an adeno-associated viral vector to deliver a microRNA that silences the production of the mutant huntingtin protein, and it is administered directly into the brain during a surgical procedure. The Phase I/II program has followed patients for up to several years, tracking both safety and signs that the therapy slows the decline that defines Huntington's disease. The four-year data that uniQure plans to present by the end of Q3 2026 will be the most important evidence yet, because Huntington's is a slowly progressive disease and the durability of a one-time gene therapy effect is the central question that regulators and clinicians will want answered.

Analysis

What this really means is that the FDA's willingness to accept a sham-surgery comparison against natural history, after initially rejecting it, signals a broader shift in how the agency is evaluating gene therapies for rare neurodegenerative diseases, and uniQure is the first company to benefit. The standard for approval in a disease like Huntington's has always been complicated by the practical impossibility of running a traditional placebo-controlled trial for a surgical gene therapy: you cannot inject a sham virus into a patient's brain without raising profound ethical questions, which is why uniQure used an external control group in the first place. The FDA's June reversal suggests the agency has concluded that the urgency of the disease and the strength of the biological rationale justify a more flexible evidentiary standard, and that conclusion will reverberate across every other gene therapy program in development.

The bigger picture here is that AMT-130 is the test case for whether gene therapy can work in the brain, the most difficult organ to treat with genetic medicines, and a successful filing would open a new chapter for the entire field. Gene therapies have transformed blood disorders and some inherited retinal diseases, but the brain has resisted them because of the blood-brain barrier, the difficulty of delivering therapy to the right cells and the risks of surgical administration. If uniQure can show that a one-time intracranial injection meaningfully slows Huntington's disease, it will validate an entire class of approaches to neurodegenerative disorders, from Parkinson's to ALS to Alzheimer's, that have been stalled for lack of a delivery mechanism. That is why the regulatory community is watching this filing so closely.

The commercial and strategic stakes are also significant. Huntington's disease is a rare disorder, and the market for AMT-130 will never rival a blockbuster drug, but gene therapies command premium prices that reflect their one-time curative potential, and uniQure has positioned itself as the leader in a niche that larger pharmaceutical companies have mostly avoided. A successful approval would give uniQure a commercial product and a platform, the delivery technology and regulatory playbook that could be applied to other CNS diseases. The company's willingness to push through the FDA's initial rejection, rather than abandoning the program, also says something about the conviction of its leadership, and about the progress of the underlying data.

Why It Matters

For the families affected by Huntington's disease, the filing is the most concrete hope in decades that the disease can be slowed or stopped, and the four-year data expected before the end of Q3 2026 will show whether that hope is justified. For the gene therapy field, AMT-130 is the leading candidate to prove that the brain can be treated with genetic medicines, and its regulatory path will shape how the FDA evaluates every CNS gene therapy that follows. For uniQure, the filing is the payoff of years of clinical investment and the beginning of the company's transition from a research-stage biotech to a commercial one. And for regulators on both sides of the Atlantic, the simultaneous US and UK applications will test whether the two agencies can align on an accelerated path for a therapy that patients cannot afford to wait for.

Next Up

In the coming weeks, watch for uniQure's presentation of the four-year Phase I/II data, which the company has said will come before the end of Q3 2026 and which will be the key evidence in the FDA's review. Watch also for the FDA's acceptance of the BLA and the priority-review decision, which will set the timeline for a decision, and for the MHRA's parallel review in the UK. The bigger question is whether the agency's flexible approach to AMT-130 extends to a full approval or is limited to an accelerated one, and whether the therapy's real-world effect, measured in patients over years, matches the promise of the biological rationale.